Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1984-5-17
|
pubmed:abstractText |
The efficacy and safety of oral amrinone were examined in 17 patients with moderately severe to severe heart failure that was refractory to standard medical therapy and vasodilators. The short-term and 28 week response to open amrinone therapy was assessed first, followed by a placebo-controlled, double-blind withdrawal study of two 13 week stages in nine patients. Rest and exercise ventricular function were determined before and after 32 hours of amrinone; aerobic capacity was serially assessed. After 2 hours, 1.64 mg/kg amrinone produced a 40% (p less than 0.001) increase in cardiac output and a 32% (p less than 0.02) decrease in pulmonary wedge pressure without altering heart rate or blood pressure. The exercise cardiac index-wedge pressure curve obtained 32 hours after the first oral dose was significantly shifted (p less than 0.05) above control values. A sustained improvement in maximal oxygen uptake was noted during long-term open amrinone therapy. Subsequently, seven of the patients randomized to placebo therapy had a significant deterioration of symptoms or exercise tolerance, or both. After 4 weeks of readministration of amrinone, clinical stability was once again established and exercise tolerance was improved by Weeks 8 to 16. Adverse effects of thrombocytopenia (one patient) and hepatic dysfunction (one patient) attributable to amrinone were observed. It is concluded that amrinone is effective in the long-term treatment of chronic cardiac failure.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0735-1097
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1282-90
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:6707381-Aged,
pubmed-meshheading:6707381-Aminopyridines,
pubmed-meshheading:6707381-Amrinone,
pubmed-meshheading:6707381-Cardiotonic Agents,
pubmed-meshheading:6707381-Chronic Disease,
pubmed-meshheading:6707381-Double-Blind Method,
pubmed-meshheading:6707381-Drug Evaluation,
pubmed-meshheading:6707381-Exercise Test,
pubmed-meshheading:6707381-Female,
pubmed-meshheading:6707381-Heart Failure,
pubmed-meshheading:6707381-Hemodynamics,
pubmed-meshheading:6707381-Humans,
pubmed-meshheading:6707381-Male,
pubmed-meshheading:6707381-Middle Aged,
pubmed-meshheading:6707381-Outpatients,
pubmed-meshheading:6707381-Oxygen Consumption,
pubmed-meshheading:6707381-Random Allocation
|
pubmed:year |
1984
|
pubmed:articleTitle |
Amrinone in the treatment of chronic cardiac failure.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|